Humanized broad-spectrum anti-HIV-1 (Human Immunodeficiency Virus-1) monoclonal antibody and application thereof

By screening single B cells from HIV-1 vaccine subjects and using flow cytometry-antibody gene amplification technology, a humanized broad-spectrum anti-HIV-1 monoclonal antibody DRVI-rTV-1 was obtained. This solved the problem of unstable antibody development pathways in existing technologies, achieving efficient neutralization of multiple HIV-1 virus strains, and is suitable for HIV-1 drugs and detection reagents.

CN121045374APending Publication Date: 2025-12-02NAT CENT FOR AIDSSTD CONTROL & PREVENTION CHINESE CENT FOR DISEASE CONTROL & PREVENTION
0 Cites 0 Cited by

Patent Information

Application Number
CN202511463489.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-14
Publication Date
2025-12-02

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively induce broad-spectrum neutralizing antibodies, and antibody development pathways are not stable or traceable in vaccine development, resulting in low efficiency in HIV-1 vaccine research.

Method used

By screening single B cells from HIV-1 vaccine subjects and using flow cytometry-antibody gene amplification technology, a humanized broad-spectrum anti-HIV-1 monoclonal antibody DRVI-rTV-1 with a unique CDR region was obtained, and the antibody was expressed in 293F cells using a eukaryotic expression vector.

Benefits of technology

The obtained antibody DRVI-rTV-1 can significantly neutralize multiple HIV-1 virus strains, making it suitable for the preparation of HIV-1 prevention and treatment drugs. It has high expression and stability, making it suitable for industrialization, and can also be used in HIV-1 virus detection reagents.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a humanized broad-spectrum anti-HIV-1 (human immunodeficiency virus-1) monoclonal neutralizing antibody, which is obtained by screening through a single B cell flow sorting-antibody gene amplification pairing expression technology, has a unique CDR (CDR region), can be specifically combined with HIV-1, and can effectively neutralize various pseudoviruses, even Tier 3 pseudoviruses. The invention also relates to a preparation method and application of the neutralizing antibody. The antibody provided by the invention can be used for emergency prevention and / or treatment of HIV-1 variant strains, has the characteristics of full human source, high expression and good stability, and is suitable for industrialization. In addition, the antibody can also be used for preparing an HIV-1 virus detection reagent, finding effective neutralizing epitopes and developing HIV-1 vaccines.
Need to check novelty before this filing date? Find Prior Art